Navigation Links
Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Date:6/4/2008

t acceptable to trade one problem for another by using potentially harmful chemicals to clean and disinfect. ESI has a single goal - reduce biological risks by destroying a wide range of disease-causing microorganisms with minimum risk to our customer, surfaces and the environment."

Methicillin Resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA is a resistant variation of the common bacterium Staphylococcus aureus. It has evolved an ability to survive treatment with beta-lactam antibiotics, including penicillin, methicillin, and cephalosporins. MRSA was discovered in 1961 in the UK and it is now found worldwide, and is often referred to in the press as a "superbug". In the past decade or so the number of MRSA infections in the United States has increased significantly. At the same time, a growing number of cases were noted in schools around the nation, with many closing their doors to scrub down their facilities. After the death of a 17-year-old Virginia student, the school district closed all 21 schools for cleaning. A 2007 report in Emerging Infectious Diseases, a publication of the Centers for Disease Control and Prevention (CDC), estimated that the number of MRSA infections treated doubled nationwide, from approximately 127,000 in 1999 to 278,000 in 2005, while at the same time deaths increased from 11,000 to more than 17,000. Another study led by the CDC and published in the October 17, 2007 issue of the Journal of the American Medical Association estimated that MRSA would have been responsible for 94,360 serious infections and associated with 18,650 hospital stay-related deaths in the United States in 2005. These figures suggest that MRSA infections are responsible for more deaths in the U.S. each year than AIDS.

Enterococci are bacteria that are normally present in the human intestines and in the urinary tract and are often found in the environment. These bacteria can sometimes cau
'/>"/>

SOURCE Anpath Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
2. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
3. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Wound Management Technologies, Inc. Announces Evidence Based Study
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
8. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
9. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
10. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
11. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CHARLOTTESVILLE, Va. and AUSTIN, ... PhosImmune Inc. and PureMHC LLC today announced they ... to develop novel antibody-based immunotherapies designed to target ... identification of phosphorylated peptides displayed on the surfaces ... These phosphopeptide tumor targets (PTTs), derived from proteins ...
(Date:10/22/2014)... 22, 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... the  IAP310 study have been published in ... peer-reviewed journal with broad, multidisciplinary readership. IAP310 was ... safety and efficacy of Zalviso, also referred to ... the treatment of post-operative pain in patients following ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 2011 /PRNewswire/ -- PRA, a leading Clinical ... Romania to further strengthen our coverage of the Balkan ... projects in the neighboring Republic of Moldova. ... in Romania, the PRA staff has steadily increased and ...
... Aug. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Assessments of Leading Suppliers ... This report provides diagnostic imaging industry ...
Cached Medicine Technology:PRA Opens Office in Romania 2Global MRI Market: Strategic Assessments of Leading Suppliers 2Global MRI Market: Strategic Assessments of Leading Suppliers 3Global MRI Market: Strategic Assessments of Leading Suppliers 4Global MRI Market: Strategic Assessments of Leading Suppliers 5
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian ... to think outside the bra. She doesn’t try to hide ... awareness about women’s other lady parts. , "We have won ... color pink and everybody knows what you’re talking about,” Jess-Huff ... has not been won when it comes to gynecologic cancers. ...
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... technology to process the conversion of medical records from microfiche to ... ... 2009 -- Penny Imaging Exchange, Inc. (PIE) has acquired new technology ... form - the DRS Digitizer . With the Obama administration ...
... CHICAGO, April 17 Specialty Underwriters, Alliance, Inc. ... announced today that Glass Lewis & Co., a leading ... WHITE proxy card and do not vote for the nominees ... SUA,s Annual Meeting of Stockholders will be held at 9:00 ...
... Volunteer Week, is April 19 - April 25 ... today praised Pennsylvania,s volunteers for selflessly giving their time ... and urged other citizens to join those important efforts. ... opportunity to thank our volunteers for generously sharing their ...
... Assurance solutions help MEDNAX increase security and simplify ... Corporation , leaders in access governance, provisioning ... implemented the company,s Enterprise Suite to assure access ... 5,000 clinical and administrative employees. MEDNAX is ...
... such study involves effort to improve chemotherapy effectiveness , , FRIDAY, ... research and testing, only a small percentage of cancer agents ... have come up with a way to weed out the ... the marketplace. , The new model, a so-called "phase ...
... South Florida physician Sanford Siegal, D.O., M.D., explains why ... and reveals how to overcome this obstacle to reaching ... Sanford Siegal, Medical Director of Miami, Florida-based weight-loss practice, ... among dieters that the most challenging part of reaching ...
Cached Medicine News:Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3Health News:PA Secretary of Health Recognizes Pennsylvania Volunteers; Urges Greater Citizen Involvement 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 3Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 2Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 3Health News:Losing the Last Ten Pounds is the Hardest Part of any Diet Confirms Weight-Loss Expert and Author Dr. Sanford Siegal 2
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... operations, the Sysmex KX-21N is ideal ... lab testing. This 3-part differential ... Built on the reliable, field proven ... a completely automatic START-UP function and ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
Medicine Products: